A candidate drug dismantles a metabolic barrier to anti-tumor immunity

A Ludwig Cancer Research study has identified a specific mode of fat uptake by immune cells within tumors that serves as a metabolic checkpoint against anti-cancer immune responses. Harnessing that insight, researchers led by Ludwig Lausanne's Ping-Chih Ho and Yi-Ru Yu - along with Sheue-Fen Tzeng and Chin-Hsien Tsai, former post-docs in the Ho lab who now lead their own labs at Taipei Medical University in Taiwan - have developed a humanized antibody to dismantle that barrier as a potential cancer immunotherapy.